HealthMore in Health →
Moderna Pays $950M to Settle COVID Vaccine Patent Fight
Moderna agrees to pay $950 million to settle long-running patent claims with Arbutus and Roivant over lipid nanoparticle technology used in its COVID vaccine.
Key Takeaways
- Moderna pays $950M upfront to settle LNP patent dispute
- Patents cover lipid nanoparticle tech critical to mRNA vaccine delivery
DE
DT Editorial AI··4 min read·via endpoints.news